SGS has invested £7.6 million in its facility in Glasgow, UK to expand the capabilities and capacity for testing cell banks and routine bulk harvest for vaccines, gene and cell therapies, monoclonal antibodies and other recombinant protein based biological medicines. The new lab added 1,200 sq. m. to the existing facility and will be adjacent to SGS’s existing global center of excellence for cell banks and viral vaccine biosafety.   The facility now totals 2,400 sq. m., employs 65 staff and pl...